SCHEMBL13321787

SCHEMBL13321787

CC(C)(C)OC(=O)CC(O)(c1ccc(F)cc1Cl)c1ccnc(-c2c(Cl)cccc2Cl)c1NC(=O)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CCNT1 O60563 4/20 0.35
▸ DGAT2 Q96PD7 1/20 0.33
▸ NPY2R P49146 3/20 0.33
▸ PDK1 Q15118 2/20 0.33
▸ PDK2 Q15119 2/20 0.33
▸ PDK3 Q15120 2/20 0.33
▸ PDK4 Q16654 2/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ EGFR P00533 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ ANO1 Q5XXA6 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ CDK9 P50750 3/20 0.31
▸ CHRNA7 P36544 1/20 0.31
▸ RORC P51449 1/20 0.31
▸ SCN5A Q14524 1/20 0.30
▸ SCN9A Q15858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13321786 0.95 CCNT1 (0.34) CCNT1DGAT2NPY2RCNR2ANO1
SCHEMBL2081557 0.94 CCNT1 (0.34) CCNT1DGAT2NPY2RPDK1PDK2
SCHEMBL13321789 0.89 PDK1 (0.34) PDK1PDK2PDK3PDK4ANO1
SCHEMBL13321788 0.87 LMNA (0.34) NPY2RPDK1PDK2PDK3PDK4
SCHEMBL2079443 0.87 FPR2 (0.32) CCNT1ANO1MAPT
SCHEMBL2080175 0.86 DGAT2 (0.39) CCNT1DGAT2MEN1KMT2A
SCHEMBL13353994 0.80 CNR2 (0.33) NPY2RPDK1PDK2PDK3PDK4
SCHEMBL2079067 0.80 ABL1 (0.34) CCNT1DGAT2CDK9
SCHEMBL4070987 0.76 P2RY1 (0.33) ANO1MAPT
SCHEMBL2829217 0.75 EGFR (0.39) PDK1PDK2PDK3PDK4CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8334294-B2 4,8-diphenyl-polyazanaphthalene derivatives ALMIRALL, S.A. (ES) 2012-12-18 — — US disclosed
US-8334294-B2 4,8-diphenyl-polyazanaphthalene derivatives ALMIRALL, S.A. (ES) 2012-12-18 — — US disclosed
US-20100130517-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES ALMIRALL, S.A. (ES) 2010-05-27 — — US disclosed
US-20100130517-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES ALMIRALL, S.A. (ES) 2010-05-27 — — US disclosed
WO-2008131922-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES ALMIRALL, S.A. (ES) 2008-11-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130517-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES MAPK8, MAPK4, MAP3K8 CCNT1 469/4885DGAT2 3393/4885NPY2R 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback